|
n
|
15
|
15
|
15
| |
|
Sex (n; Male/Female)
|
2/13
|
2/13
|
2/13
| |
|
Age (years) mean ± SD
|
13.5 ± 2.2
|
13.6 ± 2.8
|
13.7 ± 2.7
|
0.91
|
|
Tanner stage (n; I–II / III–IV)
|
4/11
|
4/11
|
4/11
| |
|
Body mass (kg) mean ± SD
|
49.3 ± 16.3
|
46.0 ± 13.5
|
48.9 ± 13.5
|
0.78
|
|
Height (cm) mean ± SD
|
155.8 ± 15.5
|
155.5 ± 14.6
|
154.9 ± 13.2
|
0.98
|
|
BMI (kg/m2) mean ± SD
|
19.6 ± 4.1
|
18.6 ± 3.0
|
20.0 ± 3.4
|
0.49
|
|
JIA subtype (n)
| | |
–
| |
|
oJIA
|
3
|
7
|
–
| |
|
pJIA RF−
|
7
|
4
|
–
| |
|
pJIA RF+
|
2
|
1
|
–
| |
|
ERA
|
2
|
1
|
–
| |
|
Psoriatic
|
1
|
1
|
–
| |
|
Undifferentiated
|
0
|
1
|
–
| |
|
Disease duration (months) mean ± SD
|
48.1 ± 31.6
|
46.7 ± 34.1
|
–
|
0.61
|
|
Disease activity a (n)
| | |
–
| |
|
Active
|
4 b
|
4 c
|
–
|
0.66
|
|
Inactive
|
11
|
11
|
–
|
|
DMARDs (n)
| | |
–
| |
|
NSAIDs
|
1
|
4
|
–
| |
|
MTX
|
8
|
8
|
–
| |
|
TNF-α blockade
|
15
|
0
|
–
| |
|
Adalimumab
|
3
|
0
|
–
| |
|
Etanercept
|
10
|
0
|
–
| |
|
Infliximab
|
2
|
0
|
–
| |
|
IPAQ score (n)
|
|
Low level of activity
|
8
|
6
|
5
|
0.69
|
|
Moderate level of activity
|
3
|
5
|
7
|
|
High level of activity
|
4
|
4
|
3
|
|
VO2peak (ml/min) mean ± SD
|
1568.8 ± 670.9
|
1464.9 ± 445.3
|
1637.3 ± 579.9
|
0.76
|
|
VO2peak/body mass (ml/kg/min) mean ± SD
|
33.0 ± 9.9
|
32.6 ± 6.0
|
33.7 ± 8.0
|
0.83
|
|
Rest metabolism (kcal/day) mean ± SD
|
1467.2 ± 427.6
|
1431.7 ± 423.7
|
1767.6 ± 622.4
|
0.14
|
